Key result
Minipool nucleic acid amplification screening for influenza viruses is feasible, demonstrating an analytical sensitivity of 804 geq/mL for generic primers and 444 geq/mL for H5N1-specific primers.
Why the study?
Is minipool nucleic acid amplification technique (NAT) screening feasible and sensitive for detecting influenza viruses in blood donor samples?
Observational (n=10,272)
Is minipool nucleic acid amplification technique (NAT) screening feasible and sensitive for detecting influenza viruses in blood donor samples?
Minipool NAT screening for influenza viruses, including H5N1, is analytically sensitive and feasible for ensuring blood safety during potential pandemics.
May support influenza screening in blood donors during outbreaks; leaves open prospective validation of transfusion safety impact.
Influenza viruses, including highly pathogenic avian influenza virus (H5N1), could threaten blood safety. We analyzed 10,272 blood donor samples with a minipool nucleic acid amplication technique. Analytical sensitivity of the method was 804 geq/mL and 444 geq/mL for generic influenza primers and influenza (H5N1) subtype-specific primers. This study demonstrates that such screening for influenza viruses is feasible.
No takes yet. Share an insight, caveat, or question.
Hourfar et al. (2007) conducted an observational in Influenza (H5N1) screening in blood donors (n=10,272). Minipool nucleic acid amplification technique (NAT) was evaluated on Analytical sensitivity (95% detection limit) for the influenza (H5N1)-specific test (95% CI 5.2-14.7). Minipool nucleic acid amplification screening for influenza viruses is feasible, demonstrating an analytical sensitivity of 804 geq/mL for generic primers and 444 geq/mL for H5N1-specific primers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: